Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab - Reply

被引：0
|
作者：
Sorbero, Melony E. S. [1 ]
ElHassan, Nahed O. [1 ]
Hall, Caroline B. [1 ]
Stevens, Timothy P. [1 ]
Dick, Andrew W. [1 ]
机构：
[1] RAND Corp, Pittsburgh, PA 15213 USA
来源：
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE | 2007年 / 161卷 / 05期
关键词：
D O I：
10.1001/archpedi.161.5.520-a
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：520 / 520
页数：1
相关论文
共 50 条
  • [31] Palivizumab prophylaxis for respiratory syncytial virus in Canada:: utilization and outcomes
    Oh, PI
    Lanctôt, KL
    Yoon, A
    Lee, DSC
    Paes, BA
    Simmons, BS
    Parison, D
    Manzi, P
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (06) : 512 - 518
  • [32] Respiratory syncytial virus prophylaxis in a high-risk population in Argentina - A cost-effectiveness analysis
    Rodriguez, Susana P.
    Farina, Diana
    Bauer, Gabriela
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (07) : 660 - 661
  • [33] Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks ' gestation in the United States
    Yu, Tianzhou
    Padula, William, V
    Yieh, Leah
    Gong, Cynthia L.
    [J]. PEDIATRICS AND NEONATOLOGY, 2024, 65 (02): : 152 - 158
  • [34] Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma
    Igde, M.
    Kabasakal, H.
    Ozturk, O.
    Karatekin, G.
    Aygun, C.
    [J]. ALLERGY, 2016, 71 : 534 - 534
  • [35] The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Lanctot, Krista L.
    Masoud, Shababa T.
    Paes, Bosco A.
    Tarride, Jean-Eric
    Chiu, Aaron
    Hui, Charles
    Francis, Philip L.
    Oh, Paul I.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3223 - 3237
  • [36] The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly
    Gessner, BD
    [J]. VACCINE, 2000, 18 (15) : 1485 - 1494
  • [37] Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis A Critical and Systematic Review
    Prescott, William A., Jr.
    Doloresco, Fred
    Brown, Jack
    Paladino, Joseph A.
    [J]. PHARMACOECONOMICS, 2010, 28 (04) : 279 - 293
  • [38] Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab
    Wang, Daniel Y.
    Saleem, Mahwesh
    Paes, Bosco A.
    Mitchell, Ian
    Li, Abby
    Lanctot, Krista L.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (08) : 775 - 780
  • [39] Impact of the risk scoring model on the cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks in Canada
    Lanctot, K. L.
    Paes, B.
    Francis, P. L.
    Chiu, A.
    Hui, C.
    Oh, P., I
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A248 - A249
  • [40] Cost minimisation of respiratory syncitial virus prophylaxis with palivizumab
    Wills, SL
    Coutts, J
    Simpson, J
    [J]. PEDIATRIC RESEARCH, 2005, 58 (02) : 426 - 426
12345